Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Astellas Pharma, Inc. has hauled back its core revenue and profit guidance for the fiscal year ending next 31 March, citing the impact of the coronavirus pandemic on various aspects of its business, although its mainstay cancer product and other oncology operations remained strong.
Addressing a results briefing for the fiscal first quarter ended 30 June, chief financial officer Naoki Okamura said “the first...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
